We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
-2.57%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$86.2B
AUM Growth
-$3.13B
(-3.5%)
Cap. Flow
+$224M
Cap. Flow
% of AUM
0.26%
Top 10 Holdings %
Top 10 Hldgs %
24.96%
Holding
4,488
New
66
Increased
2,157
Reduced
1,702
Closed
141
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Kenvue
KVUE
|
+$72.5M |
| 2 |
iShares Russell 1000 ETF
IWB
|
+$54.4M |
| 3 |
Blackstone
BX
|
+$44M |
| 4 |
Airbnb
ABNB
|
+$37.4M |
| 5 |
Everest Group
EG
|
+$30.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$57.8M |
| 2 |
LSI
Life Storage, Inc.
LSI
|
+$39.6M |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$23.8M |
| 4 |
iShares Global Infrastructure ETF
IGF
|
+$19.2M |
| 5 |
PDCE
PDC Energy, Inc.
PDCE
|
+$18.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.73% |
| 2 | Healthcare | 12.76% |
| 3 | Financials | 12.67% |
| 4 | Consumer Discretionary | 11.16% |
| 5 | Industrials | 9.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3151
ARS Pharmaceuticals
SPRY
$612M
| $137K | ﹤0.01% |
36,355
+1,924
| +6% | +$12.6K |
|
3152
HUTCHMED
HCM
$2.17B
| $137K | ﹤0.01% |
8,104
| – | – |
|
|
ERF
3153
DELISTED
Enerplus Corporation
ERF
| $135K | ﹤0.01% |
7,670
+640
| +9% | +$10.6K |
|
3154
CGI
GIB
$15.5B
| $135K | ﹤0.01% |
1,370
+80
| +6% | +$8.18K |
|
|
ESSA
3155
DELISTED
ESSA Bancorp
ESSA
| $135K | ﹤0.01% |
8,963
+447
| +5% | +$7.11K |
|
3156
Cartesian Therapeutics
RNAC
$268M
| $134K | ﹤0.01% |
4,204
+211
| +5% | +$7.05K |
|
|
KYNB
3157
Kyntra Bio
KYNB
$29.4M
| $133K | ﹤0.01% |
6,183
-353
| -5% | -$13.9K |
|
|
NOTE
3158
DELISTED
FiscalNote
NOTE
| $133K | ﹤0.01% |
5,337
+209
| +4% | +$7.15K |
|
|
LSEA
3159
DELISTED
Landsea Homes
LSEA
| $133K | ﹤0.01% |
14,781
-2,238
| -13% | -$22.4K |
|
|
NSANY
3160
DELISTED
NISSAN MOTOR CO LTD SPONS ADR
NSANY
| $133K | ﹤0.01% |
15,021
+3,890
| +35% | +$34.3K |
|
3161
Foghorn Therapeutics
FHTX
$360M
| $132K | ﹤0.01% |
26,426
+999
| +4% | +$7.7K |
|
3162
Lineage Cell Therapeutics
LCTX
$278M
| $131K | ﹤0.01% |
110,975
+6,888
| +7% | +$9.37K |
|
3163
Noodles & Co
NDLS
$107M
| $131K | ﹤0.01% |
6,654
-11,986
| -64% | -$289K |
|
3164
Rallybio
RLYB
$85.8M
| $131K | ﹤0.01% |
4,846
+73
| +2% | +$3.16K |
|
|
MAGN
3165
Magnera Corp
MAGN
$460M
| $130K | ﹤0.01% |
5,009
-48
| -0.9% | -$1.6K |
|
|
CMBM
3166
DELISTED
Cambium Networks
CMBM
| $130K | ﹤0.01% |
17,685
-1,931
| -10% | -$20.9K |
|
|
SGMO
3167
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $129K | ﹤0.01% |
215,297
+3,159
| +1% | +$3.38K |
|
|
PARAA
3168
DELISTED
Paramount Global Class A
PARAA
| $129K | ﹤0.01% |
8,159
+241
| +3% | +$4.32K |
|
3169
Veritone
VERI
$122M
| $129K | ﹤0.01% |
49,870
-16,071
| -24% | -$53.3K |
|
3170
Empire Petroleum
EP
$111M
| $129K | ﹤0.01% |
13,353
+660
| +5% | +$5.94K |
|
|
TVRD
3171
Tvardi Therapeutics
TVRD
$23.4M
| $128K | ﹤0.01% |
2,109
-20
| -0.9% | -$1.88K |
|
|
KZR
3172
DELISTED
Kezar Life Sciences
KZR
| $127K | ﹤0.01% |
10,686
-669
| -6% | -$11.9K |
|
3173
Eve Holding
EVEX
$962M
| $126K | ﹤0.01% |
15,221
+786
| +5% | +$6.83K |
|
|
PLM
3174
DELISTED
PolyMet Mining Corp.
PLM
| $125K | ﹤0.01% |
60,016
-441
| -0.7% | -$912 |
|
3175
Design Therapeutics
DSGN
$876M
| $124K | ﹤0.01% |
52,476
+886
| +2% | +$4.13K |
|
Similar funds
VAM
RhumbLine Advisers's Q3 2023 Portfolio in Review
As of Q3 2023, RhumbLine Advisers held 4,488 positions worth $86.2B, down 3.5% from $89.3B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Trading was light in Q3 2023: portfolio turnover was 4.6%. RhumbLine Advisers opened 66 new positions and exited 141, leaving the 4,488-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 27% a quarter earlier, followed by Healthcare and Financials.
- RhumbLine Advisers's largest Q3 2023 buy was Kenvue: 3,131,012 shares worth $62.9M.
- RhumbLine Advisers added most to iShares Russell 1000 ETF in Q3 2023, an estimated $54.4M increase.
- RhumbLine Advisers's biggest Q3 2023 reduction was Johnson & Johnson, cutting an estimated $57.8M.
- RhumbLine Advisers fully exited Life Storage, Inc. in Q3 2023, selling an estimated $39.6M.
- RhumbLine Advisers's ten largest holdings make up 25% of its $86.2B portfolio in Q3 2023.
- RhumbLine Advisers opened 66 new positions and closed 141 in Q3 2023.
- RhumbLine Advisers's portfolio value fell 3.5% quarter-over-quarter to $86.2B.
Based on RhumbLine Advisers's 13F filing for Q3 2023, filed 9 Nov 2023.